Opioid-containing oral pharmaceutical compositions and methods
The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).
1. A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix;
a therapeutically effective amount of an opioid selected from the group consisting of hydrocodone, tramadol, salts thereof, and combinations thereof;
a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof; and
a pharmaceutically acceptable anionic surfactant selected from the group consisting of sodium lauryl sulfate, docusate sodium, docusate calcium, and combinations thereof;
wherein the opioid, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.
2. The composition of claim 1 which exhibits a release profile with respect to the opioid comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.
3. The composition of claim 1 wherein the opioid is selected from the group consisting of hydrocodone, a salt thereof, and combinations thereof.
4. The composition of claim 3 wherein the opioid comprises hydrocodone bitartrate.
5. The composition of claim 1 wherein the opioid is selected from the group consisting of tramadol, a salt thereof, and combinations thereof.
6. The composition of claim 5 wherein the opioid comprises tramadol hydrochloride.
7. The composition of claim 1 wherein the pharmaceutically acceptable anionic surfactant is docusate sodium.
8. The composition of claim 1 wherein the matrix comprises a cellulose ether.
9. The composition of claim 8 wherein the cellulose ether comprises a hydroxyalkyl cellulose, a carboxyalkyl cellulose, and combinations thereof.
10. The composition of claim 1 wherein the matrix comprises a methylcellulose, a hydroxypropyl methylcellulose, and combinations thereof.
11. The composition of claim 1 wherein the matrix comprises a hydroxypropyl methylcellulose.
12. A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix comprising a hydroxypropyl methylcellulose;
a therapeutically effective amount of an opioid selected from the group consisting of hydrocodone, a salt thereof, and combinations thereof;
a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, and combinations thereof; and
a pharmaceutically acceptable anionic surfactant selected from the group consisting of docusate sodium, docusate calcium, and combinations thereof;
wherein the opioid, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.
13. The composition of claim 12 which exhibits a release profile with respect to the opioid comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.
14. The composition of claim 12 wherein the opioid comprises hydrocodone bitartrate.
15. The composition of claim 12 wherein the pharmaceutically acceptable anionic surfactant is docusate sodium.
16. The composition of claim 12 wherein the salt of an NSAID comprises naproxen sodium.
17. A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix comprising a hydroxypropyl methylcellulose;
a therapeutically effective amount of an opioid selected from the group consisting of tramadol, a salt thereof, and combinations thereof;
a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, and combinations thereof; and
a pharmaceutically acceptable anionic surfactant selected from the group consisting of docusate sodium, docusate calcium, and combinations thereof;
wherein the opioid, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.
18. The composition of claim 17 which exhibits a release profile with respect to the opioid comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.
19. The composition of claim 17 wherein the opioid comprises tramadol hydrochloride.
20. The composition of claim 17 wherein the pharmaceutically acceptable anionic surfactant is docusate sodium.